# EDGAR Filing Document

**Accession Number:** 0001789972
**File Stem:** 0001193125-26-099373
**Filing Date:** 2026-3
**Character Count:** 17020
**Document Hash:** 0678048a3fb68dbbb7ad96543e518ec0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-099373.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001193125-26-099373

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cullinan Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001789972
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813879991
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294168
- **FILM NUMBER:** 26737241

**BUSINESS ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-410-4650

**MAIL ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Oncology, Inc.
- **DATE OF NAME CHANGE:** 20210225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Management, Inc.
- **DATE OF NAME CHANGE:** 20210107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Oncology, LLC
- **DATE OF NAME CHANGE:** 20191001

**As filed with the Securities and Exchange Commission on March 10, 2026**

Registration No. 333-_____

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

------

**FORM S-8**

------

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

------

**CULLINAN THERAPEUTICS, INC.** 

(Exact name of registrant as specified in its charter)

------

---

| | |
|:---|:---|
| **Delaware** | **81-3879991** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **One Main Street**<br>**Suite 1350**<br>**Cambridge, MA** | **02142** |
| (Address of principal executive offices) | (Zip Code) |

---

**Cullinan Therapeutics, Inc. 2021 Stock Option and Incentive Plan<br>Cullinan Therapeutics, Inc. 2021 Employee Stock Purchase Plan**

(Full Title of the Plan)

**Nadim Ahmed**

**President and Chief Executive Officer**

**Cullinan Therapeutics, Inc.**

**One Main Street**

**Suite 1350**

**Cambridge, MA 02142**<br> (Name and Address of Agent For Service)

**(617) 410-4650**

(Telephone Number, Including Area Code, of Agent For Service)

------

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

# Statement of Incorporation by Reference

# This Registration Statement on Form S-8, relating to the 2021 Stock Option and Incentive Plan (thre "2021 Stock Plan") of Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (the "Registrant") and the 2021 Employee Stock Purchase Plan of the Registrant (the "ESPP"), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-251943, filed with the Securities and Exchange Commission (the "SEC") on [<u>January 7, 2021</u>](https://www.sec.gov/Archives/edgar/data/1789972/000119312521004254/d106166ds8.htm) by the Registrant, relating to the 2021 Stock Plan and the ESPP, (ii) the Registration Statement on Form S-8, File No. 333-263428, filed with the SEC on [<u>March 10, 2022</u>](https://www.sec.gov/Archives/edgar/data/1789972/000119312522072010/d309484ds8.htm) by the Registrant, relating to the 2021 Stock Plan and the ESPP, (iii) the Registration Statement on Form S-8, File No. 333-270387, filed with the SEC on [<u>March 9, 2023</u>](https://www.sec.gov/Archives/edgar/data/1789972/000119312523065392/d482100ds8.htm) by the Registrant relating to the 2021 Stock Plan and the ESPP, (iv) the Registration Statement on Form S-8, File No. 333-277914, filed with the SEC on [<u>March 14, 2024</u>](https://www.sec.gov/Archives/edgar/data/1789972/000095017024031144/s-8_2024.htm) by the Registrant relating to the 2021 Stock Plan and the ESPP, (v) the Registration Statement on Form S-8, File No. 333-285302, filed with the SEC on [<u>February 27, 2025</u>](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028351/cgem-20250227.htm) by the Registrant relating to the 2021 Stock Plan and the ESPP, except for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.

## Item 8. Exhibits.
The following exhibits are incorporated herein by reference:

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 4.1 | [<u>Second Amended and Restated Certificate of Incorporation of the Registrant, as amended by the Certificate of Amendment, effective as of April 15, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</u>](https://www.sec.gov/Archives/edgar/data/1789972/000095017024060535/cgem-ex3_1.htm) |
| 4.2 | [<u>Third Amended and Restated Bylaws of the Registrant, effective as of April 15, 2024 (incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K filed with the SEC on April 16, 2024).</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001789972/000095017024044593/cgem-20240415.htm) |
| 5.1\* | [<u>Opinion of Ropes & Gray LLP, counsel to the Registrant.</u>](cgem-ex5_1.htm) |
| 23.1\* | [<u>Consent of Ropes & Gray LLP (included in Exhibit 5.1).</u>](cgem-ex5_1.htm) |
| 23.2\* | [<u>Consent of KPMG LLP, Independent Registered Public Accounting Firm.</u>](cgem-ex23_2.htm) |
| 24.1\* | [<u>Power of Attorney (included on the signature pages of this registration statement).</u>](#powerofattorney) |
| 99.1 | [<u>2021 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant's Registration Statement on Form S-1 (File No. 333-251512) filed with the SEC on January 4, 2021).</u>](https://www.sec.gov/Archives/edgar/data/1789972/000119312521000161/d19045dex101.htm) |
| 99.2 | [<u>2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant's Registration Statement on Form S-1 (File No. 333-251512) filed with the SEC on January 4, 2021).</u>](https://www.sec.gov/Archives/edgar/data/1789972/000119312521000161/d19045dex102.htm) |
| 107\* | [<u>Filing Fee Table.</u>](cgem_exfilingfees.htm) |

---

------

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 10th day of March, 2026.

---

| | | |
|:---|:---|:---|
|  | **Cullinan Therapeutics, Inc.** | **Cullinan Therapeutics, Inc.** |
| Date: March 10, 2026 | By: | /s/ Nadim Ahmed |
|  |  | Name: Nadim Ahmed |
|  |  | Title: President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Cullinan Therapeutics, Inc., hereby severally constitute and appoint Nadim Ahmed and Mary Kay Fenton, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cullinan Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Nadim Ahmed | President, Chief Executive Officer and Director  | March 10, 2026 |
| **Nadim Ahmed** | (Principal Executive Officer) |  |
| /s/ Mary Kay Fenton | Chief Financial Officer  | March 10, 2026 |
| **Mary Kay Fenton** | (Principal Financial and Accounting Officer) |  |
| /s/ Andrew Allen, M.D., Ph.D. |  | March 10, 2026 |
| **Andrew Allen, M.D., Ph.D.** | Director |  |
| /s/ Mittie Doyle, M.D., FACR |  | March 10, 2026 |
| **Mittie Doyle, M.D., FACR** | Director |  |
| /s/ David Meek |  | March 10, 2026 |
| **David Meek** | Director |  |
| /s/ Anthony Rosenberg |  | March 10, 2026 |
| **Anthony Rosenberg** | Director |  |
| /s/ Mary Thistle |  | March 10, 2026 |
| **Mary Thistle** | Director |  |
| /s/ Stephen Webster |  | March 10, 2026 |
| **Stephen Webster** | Director |  |

---

------

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![img133713030_0.jpg](img133713030_0.jpg) | ROPES & GRAY LLP<br>PRUDENTIAL TOWER<br>800 BOYLSTON STREET<br>BOSTON, MA 02199-3600<br>WWW.ROPESGRAY.COM |

---

March 10, 2026

Cullinan Therapeutics, Inc.

One Main Street, Suite 1350

Cambridge, MA 02142

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by Cullinan Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of 3,614,648 additional shares of Common Stock, $0.0001 par value per share, of the Company (the "<u>Shares</u>"). Of this amount, 602,441 of the Shares are issuable under the Company's 2021 Employee Stock Purchase Plan (the "<u>ESPP</u>"), and 3,012,207 of the Shares are issuable under the Company's 2021 Stock Option and Incentive Plan (together with the ESPP, the "<u>Plans</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plans, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

------

## Exhibit 23.2

**Exhibit 23.2**

---

| | |
|:---|:---|
| ![img108548027_0.jpg](img108548027_0.jpg) | KPMG LLP<br>Two Financial Center<br>60 South Street<br>Boston, MA 02111 |

---

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 10, 2026, with respect to the consolidated financial statements of Cullinan Therapeutics, Inc., incorporated herein by reference.

---

| |
|:---|
| /s/ KPMG LLP |
| Boston, Massachusetts |
| March 10, 2026 |

---

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107.1**

**Calculation of** Filing Fee **Tables**

**Form** S-8

(Form Type)

Cullinan Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Security Type | &nbsp;&nbsp;**Security Class Title** | &nbsp;&nbsp;**Maximum<br>Aggregate Offering<br>Price**<br>| &nbsp;&nbsp;**Fee Rate** | &nbsp;&nbsp;**Amount of Registration<br>Fee**  |
| &nbsp;&nbsp;Equity | &nbsp;&nbsp;Common stock, $0.0001 par value per share <br> &nbsp;&nbsp;Other <sup>(2)</sup><br>&nbsp;&nbsp;602441 <sup>(3)</sup><br>&nbsp;&nbsp;$13.08 <sup>(2)</sup> | &nbsp;&nbsp;$7879928.28 | &nbsp;&nbsp;0.0001381 | &nbsp;&nbsp;$1088.22 |
| &nbsp;&nbsp;Equity | &nbsp;&nbsp;Common stock, $0.0001 par value per share <br> &nbsp;&nbsp;Other <sup>(4)</sup><br>&nbsp;&nbsp;3012207 <sup>(5)</sup><br>&nbsp;&nbsp;$15.39 <sup>(4)</sup> | &nbsp;&nbsp;$46357865.73 | &nbsp;&nbsp;0.0001381 | &nbsp;&nbsp;$6402.02 |
| &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;$54237794.01 |  | &nbsp;&nbsp;$7490.24 |
| &nbsp;&nbsp;**Total Fee Offsets** <sup>(6)</sup> | &nbsp;&nbsp;**Total Fee Offsets** <sup>(6)</sup> |  |  | &nbsp;&nbsp;**-** |
| &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** |  |  | &nbsp;&nbsp;$7490.24 |

---

(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 ("Registration Statement") shall also cover any additional shares of the common stock of Cullinan Therapeutics, Inc. (the "Registrant") that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant's receipt of consideration that results in an increase in the number of the outstanding shares of the Registrant's common stock.

(2)Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share is equal to 85% of $15.39, which was computed by averaging the $15.95 (high) and $14.82 (low) prices of a share of the Registrant's common stock as reported on The Nasdaq Global Select Market on March 6, 2026. Under the 2021 ESPP, the purchase price of a share of common stock is equal to 85% of the fair market value of the Registrant's common stock on the offering date or the exercise date, whichever is less.

(3)Represents additional shares of the Registrant's common stock automatically reserved and available for issuance under the Registrant's 2021 Employee Stock Purchase Plan (the "2021 ESPP") resulting from the annual "evergreen" increase in the number of authorized shares reserved and available for issuance under the 2021 ESPP on January 1, 2026. The annual increase was equal to one percent (1%) of the number of shares of common stock issued and outstanding on December 31, 2025.

(4)Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $15.39 was computed by averaging the $15.95 (high) and $14.82 (low) prices of a share of the Registrant's common stock as reported on The Nasdaq Global Select Market on March 6, 2026.

(5)Represents additional shares of the Registrant's common stock automatically reserved and available for issuance under the Registrant's 2021 Stock Option and Incentive Plan (the "2021 Plan") resulting from the annual "evergreen" increase in the number of authorized shares reserved and available for issuance under the 2021 Plan on January 1, 2026. The annual increase was equal to five (5%) percent of the number of shares of stock issued and outstanding on December 31, 2025.

(6)The Registrant does not have any fee off-sets.

------